- Report
- October 2024
- 197 Pages
Global
From €3386EUR$3,545USD£2,831GBP
€3762EUR$3,939USD£3,146GBP
- Report
- June 2024
- 200 Pages
Global
From €7593EUR$7,950USD£6,349GBP
- Clinical Trials
- May 2024
- 102 Pages
Global
From €2388EUR$2,500USD£1,997GBP
- Clinical Trials
- March 2025
- 60 Pages
Global
From €1194EUR$1,250USD£998GBP
- Report
- December 2022
- 70 Pages
Global
From €3338EUR$3,495USD£2,791GBP
- Report
- January 2025
- 132 Pages
Global
From €907EUR$950USD£759GBP
The CIDP Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. CIDP Drugs are used to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder that affects the peripheral nervous system. CIDP Drugs are typically immunomodulatory agents, such as corticosteroids, intravenous immunoglobulin (IVIg), and plasma exchange. These drugs are used to reduce inflammation and improve nerve conduction.
The CIDP Drug market is highly competitive, with several major players. Companies such as Pfizer, Merck, and Novartis are leading the market with their immunomodulatory agents. Other companies such as Biogen, Sanofi, and AbbVie are also active in the CIDP Drug market, offering a range of treatments for CIDP. Show Less Read more